---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-032956"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:36:22.984928+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Benitec Q2 net loss $6.8M; first BB-301 subject cleared DSMB review – enrollment continues

## Summary
- Net loss of $6.8M ($2.64 per share) for quarter ended Dec 31, 2023 vs $5.4M ($3.34) a year ago.
- Cash and cash equivalents $20.4M at Dec 31, 2023, up from $2.5M at June 30, 2023.
- First subject dosed with BB-301 in Nov 2023; DSMB review found no dose-limiting toxicities, recommended continuation without modifications.
- 23 subjects enrolled in OPMD natural history study; second subject scheduled to receive BB-301 in Feb 2024.
- Interim safety and efficacy data from Phase 1b/2a Clinical Treatment Study expected mid-2024.

## SEC filing metadata
- accession: 0001193125-24-032956
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312524032956/0001193125-24-032956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312524032956/d756179d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-032956
- JSON: https://secwatch.observer/filing/0001193125-24-032956.json
- Plain text: https://secwatch.observer/filing/0001193125-24-032956.txt

## Key facts
- Earnings Releases
  Benitec Biopharma Inc. reported financial results for fiscal quarter ended December 31, 2023.
  - Period: fiscal quarter ended December 31, 2023
  - Result: reported results
  source text: On February 13, 2024, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312524032956/0001193125-24-032956-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.